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Abstract
Patients with defective ectodysplasin A (EDA) have X-linked hypohidrotic ectodermal dysplasia
(XLHED; OMIM#305100), a condition comprising hypotrichosis, inability to sweat, abnormal
teeth, and frequent pulmonary infections. The XLHED dogs show the same clinical signs as
humans with the disorder, including frequent respiratory infections that can be fatal. The
respiratory disease in humans and dogs is thought to be due to the absence of tracheal and
bronchial glands which are a vital part of the mucociliary clearance mechanism. In our XLHED
model, the genetically missing EDA was replaced by post-natal intravenous administration of
recombinant EDA resulting in long-term, durable corrective effect on adult, permanent dentition.
After treatment with EDA, significant correction of the missing tracheal and bronchial glands was
achieved in those dogs that received higher doses of EDA. Moreover, successful treatment
resulted in the presence of esophageal glands, improved mucociliary clearance, and the absence of
respiratory infection. These results demonstrate that a short-term treatment at a neonatal age with a
recombinant protein can reverse a developmental disease and result in vastly improved quality of
life.
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INTRODUCTION
X-linked hypohidrotic/anhidrotic ectodermal dysplasia (XLHED) in humans (MIM
#305100), manifests by hypoplasia of hair and eccrine sweat glands [Bears et al., 1987;
Clarke, 1987; Clarke et al., 1987]. Other milder clinical signs of XLHED are sparse or
absent hair, absent and malformed teeth, skin hyperpigmentation around the eyes, wrinkled,
dry skin, atopy, recurrent benign infections, and increased susceptibility to bronchitis and
pneumonia [Clarke et al., 1987; Gilenkrantz et al., 1989; Nordgarden et al., 2001; Reed et
al., 1970; Siegel et al., 1990; Soderholm et al., 1985].
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There is significant morbidity and mortality in affected children due to hyperthermia
because of their inability to sweat and due to an increased risk of respiratory tract infections
because they lack nasal, tracheal, and bronchial glands [Bears et al., 1987; Clarke et al.,
1987; Kere et al., 1996; Reed et al., 1970; Spiegel et al., 1990; Soderholm et al., 1985]. As
in human patients with XLHED, affected dogs lack respiratory glands and are at an
increased risk for pulmonary disorders [Casal et al., 2005, 2007]. Over the years we have
been maintained an XLHED dog colony; almost all affected dogs exhibited chronic nasal
discharge and nasal crusts, and mild to fatal bronchopneumonia was seen in almost half of
the affected dogs [Casal et al., 2005].
Analogous to experiments performed in Tabby mice, the mouse homologue of human and
canine XLHED [Gaide et al., 2003], recombinant ectodysplasin A (Fc:EDA1) was
administered neonatally to XLHED pups in an attempt to reverse the disease. Previously, we
had shown that postnatal administration of Fc:EDA1 has a prominent effect on permanent
dentition and significantly improved long-term resistance to eye and airways infections
[Casal et al., 2007]. The findings presented here demonstrate that the absence of pulmonary
disease is a direct consequence of restoration of tracheal and bronchial glands after postnatal
administration of Fc:EDA1 and thus improved/normalized mucociliary clearance.
MATERIALS AND METHODS
Treatment and clinical evaluation of XLHED dogs
Two affected pups received a single injection of 2 mg (7.1 mg/kg) of Fc:EDA1 [Gaide et al
2003] IV via the jugular vein 2 days after birth (T2×1 protocol). One XLHED pup was
injected with 1 mg Fc:EDA1 on 2 (3.5 mg/kg), 5 (2.2 mg/kg), 8 (2.8 mg/kg), and 11 (1.8
mg/kg) days after birth (T1×4 protocol) and four XLHED dogs received a higher dose of 2
mg (7 to 2 mg/kg with the doses decreasing with increasing age) Fc:EDA1 on days 2, 5, 8,
11, and 14 after birth (T2×5 protocol). All dogs were cared for according to the principles
outlined in the NIH Guide for the Care and Use of Laboratory Animals and in the
International Guiding Principles for Biomedical Research Involving Animals.
All dogs were observed daily and physical examinations were performed once weekly or as
needed if abnormal clinical signs were seen. Mucociliary clearance studies were performed
as described [Casal et al., 2005].
Histopathologic evaluation
Complete necropsies were performed in all dogs including an untreated normal and an
untreated affected control. The samples were reviewed by one investigator (EAM) blinded
to the treatment group. Tissues were harvested at necropsy from the proximal trachea and
esophagus as well as bronchi with adjacent pulmonary tissue. Each sample was fixed in 10%
neutral buffered formalin, routinely processed and sectioned at 5 microns and stained with
hematoxylin and eosin.
RESULTS
Clinical evaluation
No nasal discharge, sneezing, coughing or respiratory distress was seen in the treated
XLHED dogs or the normal male sibling. The untreated XLHED dog had chronic nasal
discharge, and one episode of clinical signs compatible with bronchopneumonia.
Mucociliary clearance was significantly improved in the one dog that received 2 mg of the
recombinant protein at 2 days of life and in 3 of 4 dogs that received the T2×5 treatment
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protocol, but not in the dog with the T1×4 treatment (Table I). Adult dentition was also
corrected in the same dogs.
Histopathologic evaluation (Table I)
In the normal dog (E120), numerous seromucinous glands were located in the submucosa of
all bronchi. Bronchial glands were completely absent, as predicted, in the untreated control
dog (E215). The three dogs that received either the T2×1 or T1×4 treatment (E192, E193,
and E201) had no bronchial glands. Three dogs that received a total dose of 10 mg (T2×5
treatment) (E140, E173, and E174) had bronchial glands subjectively equal to or slightly
fewer than the normal dog (Fig 1). The fourth dog that received the 10 mg treatment (E151)
had some scattered bronchial glands but fewer than those seen in the other 10 mg-dosed
dogs. The bronchial glands were used for statistical evaluation due to even distribution in all
tissue sections.
The normal control dog (E120) had numerous tracheal and esophageal glands unevenly
distributed within each section. No glands were present in either tissue in the untreated dog
(E215). In general, the treated dogs had both esophageal and tracheal glands but the glands
were sporadically distributed in the tissues (Fig. 2, Fig 3). Dogs in all treatment groups had
tracheal glands, which varied from 10–49% of the control (E151, E192, E201) to 50–75%
(E173, E174, E193). E140 had numerous tracheal glands, which were indistinguishable from
the normal dog (E120). Esophageal glands were equal in number to that of the control dog in
E140, E173, and E192. No esophageal glands were present in E193. E174 and E201 had few
glands (10–49%), while E151 had moderately fewer glands than the control (50–74%).
DISCUSSION
Chronic respiratory infections including rhinitis, tracheitis, bronchitis, and pneumonia are
common in patients with XLHED [Beahrs et al., 1971; Clarke 1987; Clarke et al., 1987;
Clarke et al., 1987; Kere et al., 1996; Reed et al., 1970; Soderholm et al., 1985]. The rhinitis
has often been described as a foul smelling nasal discharge with a tendency towards
crusting, which may lead to obstruction [Al-Jassim et al., 1987; Beahrs et al., 1971; Reed et
al., 1970; Siegel et al., 1990]. Early observations pointed out the lack of mucus in XHLED
patients, especially when compared to normal individuals who generally produce excessive
amounts of mucus in the presence of a respiratory infection, and it was thought the mucous
glands had atrophied in affected patients [Beahrs et al., 1971]. Respiratory cilia were
described as being absent or defective [Beahrs et al., 1971], but later studies confirmed that
the cilia were normal in their beating frequency and pattern, but their number was reduced
[Al-Jassim et al., 1987]. Other studies examining XLHED patients with respiratory diseases
were able to demonstrate the absence of mucous glands in the respiratory tract as well as the
esophagus, suggesting that excessive dryness of these tissues led to the lack of protective
functions and thus all of clinical findings [Beahrs et al., 1971; Clarke 1987; Clarke et al.,
1987; Reed ,., 1970]. Histological evaluations of one affected patient confirmed the lack of
mucous glands in pharynx, larynx, trachea, large and small bronchi, and upper esophagus
[Reed et al., 1970]. An early paper described the possibility of asthma as a cause for the
frequent respiratory tract infections in XHLED patients [Beahrs et al., 1971], but later
studies showed that the lack of mucus production was directly related to the increased
tendency for asthma [Siegel et al., 1990].
Pulmonary disease has not been described as a sequela to ectodermal dysplasia in the Tabby
mouse. Our XLHED dogs, however, have consistently shown signs of respiratory tract
disease, which were fatal in two cases. Earlier studies demonstrated the lack of tracheal and
bronchial glands, decreased mucociliary clearance, and frequent pneumonia [Casal et al.,
2005]. In this same study we were able to show that the respiratory immunity did not appear
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to be impaired. Interestingly, one paper describes an increased tendency for respiratory
infections in human carrier females [Clarke et al., 1987]. None of our female carrier dogs
have had respiratory infections to our knowledge.
Previously, we had shown that neonatal treatment with recombinant EDA resulted in
correction of secondary dentition and improvement of lacrimation, sweating ability, and
mucociliary clearance [Casal et al., 2007]. Studies performed in fetal Tabby mice
demonstrated that the earlier the treatment was initiated in life, the more complete the
correction from affected phenotype to wild-type normal [Gaide et al., 2003]. Many of the
typical manifestations were corrected such as the ability to sweat and dental abnormalities or
were greatly improved (hair abnormalities). However, evaluating the respiratory components
of XLHED is difficult in mice, as they do not show clinical signs of pulmonary disease. The
XLHED dog provides a model in which many of the clinical signs mimic those found in
humans much more accurately [Casal et al., 2007]. Of the first 20 affected dogs born in our
facility, 6 (35%) died before weaning of pulmonary disease. Normal preweaning losses
during the same time frame were 3 (7%) of 44 phenotypically normal littermates. Of the
remaining 14 affected dogs, 5 males were adopted out to private homes. All of the XLHED
dogs had frequent crusty nasal discharge. Four of the dogs in private homes, each developed
two bouts of pneumonia throughout their lifetime and one was treated for three episodes.
The 9 remaining adult XLHED dogs developed respiratory illnesses early in life and most
improved as they aged. However, one male and one female died of bronchopneumonia.
These previous observations demonstrate the significance of pulmonary disease in
individuals affected with XLHED and the need for treatment that is aimed at restoring
function rather than just treating secondary illness.
Clinical signs of respiratory disease are present in almost all of the affected dogs particularly
during adolescence and are also very common in humans affected with XLHED. The results
presented here demonstrate that partial to complete restoration of the tracheal and bronchial
glands is possible after neonatal administration of recombinant EDA. The appearance of the
respiratory glands greatly improved mucociliary clearance. Improved clearance correlated
with the presence of numerous glands in the respiratory tract. Interestingly, the treated
XLHED dogs never showed signs of respiratory illness, nor did they experience nasal
discharge. This was also true for those dogs in which mucociliary clearance was not
detectably improved. Taken together, these data suggests that the presence of even a few
glands in the respiratory tract is already sufficient to achieve clinical benefit.
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Figure 1.
Correction of bronchial glands in XLHED treated dogs. a. Bronchus of normal control dog
(E120) with numerous seromucinous glands (arrows). b. Untreated XLHED dog (E215) with
complete absence of bronchial glands. c. Treated XLHED dog (E140) with numerous
bronchial glands. H&E; Bar = 200 µm. Higher magnification of normal (d), untreated
XHLED (e) and treated XHLED dog (f), respectively. H&E, Bar= 100 µm.
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Figure 2.
Correction of tracheal glands in XHLED dogs. a. Tracheal mucosa of normal dog (E120)
with numerous seromucinous glands. b. Complete absence of glands in untreated XLHED
dog (E215). c. Numerous glands in treated XHLED dog (E140). H&E, Bar = 200 µm.
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Figure 3.
Correction of esophageal glands in XHLED treated dogs. a. Normal control dog (E120) with
numerous seromucinous glands. b Untreated dog with XHLED (E215) with complete lack of
glands lining the esophagus (E215). c. Treated XLHED dogs (E140) with numerous glands.
H&E, Bar = 200 µm
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